TLDR
- GSK Q2 turnover hit £8.41 billion, beating the £8.24 billion analyst consensus
- Core EPS of 50.5 pence topped the 47.1 pence forecast
- Specialty Medicines rose 14%, Vaccines up 8%; General Medicines fell 9%
- GSK launched a £1.9 billion ($2.52 billion) three-year cost-savings program
- Full-year 2026 guidance reaffirmed, with turnover growth expected at the upper half of 3%–5%
GSK stock climbed 4.2% on Tuesday after the British drugmaker reported second-quarter results that beat analyst expectations across the board and announced a major cost-cutting plan.
Q2 turnover came in at £8.41 billion, ahead of the £8.24 billion consensus. Core operating profit was £2.80 billion versus the £2.68 billion forecast.
Core profit before tax hit £2.68 billion, topping the £2.52 billion estimate. Core EPS of 50.5 pence beat the 47.1 pence consensus.
GSK Q2 2026 Earnings
-Adj EPS 50.5P (est 46.8P)
-Rev. GBP 8.41B (est GBP 8.25B)
-Vaccines Sales GBP 2.28B (Est GBP 2.1B)
-SHINGRIX Rev. GBP 888M (est GBP 867.8M)
-AREXWY REV. GBP 192M (est GBP 77.8M)
-Expect 20+ Phase III Trial Starts In 2026
-On Track For 2031 Sales…
— First Squawk (@FirstSquawk) July 28, 2026
GSK declared a Q2 dividend of 17 pence per share, in line with analyst expectations.
Specialty Medicines was the standout performer, with sales rising 14% to £3.8 billion. Oncology grew 17% and HIV climbed 10%.
Vaccines sales reached £2.3 billion, up 8%. Shingrix brought in £0.9 billion, a 3% rise, while Meningitis sales more than doubled to £0.2 billion.
Not everything moved in the right direction. General Medicines fell 9% to £2.3 billion. Trelegy sales dropped 7% to £0.8 billion.
$2.5 Billion Savings Drive
Alongside the earnings, GSK launched a £1.9 billion ($2.52 billion) three-year cost-savings program. The plan is designed to free up capital to fund late-stage drug development.
CEO Luke Miels said the program will “simplify the organisation and reallocate capital and resources” to support the late-stage pipeline.
The savings will partly fund what Miels has described as a push for faster drug development — a key priority as GSK faces upcoming patent losses on several products.
R&D and UK Investment
GSK also confirmed a £400 million investment in the UK, which includes a new R&D centre. The announcement adds to a broader push under Miels to rebuild the company’s pipeline.
GSK has been active on the acquisition front. In June, it completed what was described as its biggest-ever deal — the acquisition of Nuvalent — as it builds out its oncology business.
The company has a target of generating more than £40 billion in annual revenue by 2031. Patent losses in the coming years are seen as a key risk to hitting that goal.
GSK reaffirmed its full-year 2026 guidance, now pointing to the upper half of its 3%–5% turnover growth range.
The stock was up 4.2% at 1120 GMT on Tuesday.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
